You are viewing: UK Humanized Mouse and Rat Model Market analysis

The UK Humanized Mouse and Rat Model Market was valued at $18.1 Million in 2025 and projected to reach to $27.3 Million by 2030, representing a compound annual growth rate of 8.6%. The UK humanized mouse and rat model market is poised for sustained expansion, growing at a CAGR of 8.6% from 2025 to 2030, reaching $27.3 million by forecast end.

UK Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Humanized Mouse and Rat Model Market Trends and Insights

  • The UK's advanced pharmaceutical and biotechnology research infrastructure, combined with strong regulatory support for in vivo preclinical studies, positions the country as a key hub for humanized model adoption.
  • UK-based contract research organizations and academic institutions are increasingly leveraging these models to accelerate drug development and reduce reliance on traditional animal testing methods. Driving this expansion, the UK market benefits from substantial investment in life sciences research, a skilled workforce in genetic engineering, and growing demand from UK pharmaceutical companies for more predictive disease models.
  • Between 2025 and 2030, the UK is expected to see heightened adoption across oncology, immunology, and infectious disease research.
  • The regulatory environment in the UK, particularly post-Brexit alignment with international standards, continues to support innovation in humanized model development and commercialization. The UK's competitive advantage lies in its concentration of world-class research institutions and biotech firms that drive demand for advanced preclinical tools.
  • As the UK market grows at 8.6% annually through 2030, stakeholders are positioning themselves to capture opportunities in both domestic research and export markets across Europe..

Key Market Statistics

  • CAGR (2025-2030) 8.6% CAGR
  • Market Size, 2025 ~USD 18.1 Million
  • Forecast, 2030 ~USD 27.3 Million
  • Country UK

UK Humanized Mouse and Rat Model Market Overview

Market Valuation :

The UK humanized mouse and rat model market is valued at $18.1 million in 2025, with strong growth trajectory positioning it as a significant segment within European preclinical research.

Research Infrastructure Leadership :

The UK's world-class pharmaceutical and biotechnology research ecosystem, including leading universities and research institutions, drives high adoption rates of humanized animal models for drug development.

Regulatory Environment :

UK regulatory bodies provide robust support for in vivo preclinical studies, with established frameworks that encourage the use of humanized models to reduce animal testing burden and improve translational outcomes.

CRO Hub Status :

The UK hosts numerous contract research organizations specializing in humanized model services, creating a competitive landscape that accelerates innovation and accessibility for domestic and international pharmaceutical companies.

UK Humanized Mouse and Rat Model Market Dynamics

  • This growth is underpinned by increasing investment in precision medicine research, rising demand for more predictive preclinical models, and the UK's commitment to the 3Rs principle (Replacement, Reduction, Refinement) in animal research.
  • Pharmaceutical companies and academic institutions are increasingly adopting humanized models to improve drug efficacy predictions and reduce late-stage clinical trial failures.
  • The UK's strategic position as a global research hub, combined with supportive regulatory frameworks and access to specialized CRO services, ensures continued market momentum and attracts international research partnerships..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The UK humanized mouse and rat model market is valued at $18.1 million in 2025 and will reach $27.3 million by 2030, growing at 8.6% CAGR.
    • The UK's advanced research infrastructure and regulatory environment make it a leading European hub for humanized model adoption and development.
    • UK pharmaceutical and biotech companies are driving demand for humanized models across oncology, immunology, and infectious disease research applications.
    • Strong investment in life sciences and a skilled genetic engineering workforce position the UK for sustained market expansion through 2030.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    UK Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES2.52.62.72.93.13.33.53.76.2
    CROS AND CDMOS4.24.54.95.466.67.27.910.1
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES9.29.710.511.412.413.414.515.78.4
    TOTAL15.916.718.119.821.523.325.227.38.6

    Target Audience

    • UK Pharmaceutical Companies : Need market intelligence to optimize preclinical development strategies, evaluate humanized model adoption ROI, and benchmark against competitors in the UK market for drug discovery and development.
    • Contract Research Organizations (CROs) : Require detailed market sizing and growth forecasts to identify service expansion opportunities, justify investment in humanized model capabilities, and compete effectively within the UK preclinical services sector.
    • Academic & Research Institutions : Seek market data to support funding applications, justify infrastructure investments in humanized model facilities, and understand demand from industry partners for collaborative research opportunities in the UK.
    • Biotech & Life Sciences Investors : Need UK-specific market analysis to evaluate investment opportunities in humanized model companies, assess market growth potential, and identify strategic acquisition or partnership targets within Britain's research ecosystem.
    • Regulatory & Policy Bodies : Require market intelligence to inform policy decisions on animal research regulations, assess the economic impact of the 3Rs principle, and understand trends in humanized model adoption across UK research institutions.

    Key Companies in the UK Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise UK market valuations ($18.1M in 2025, $27.3M in 2030) and growth metrics (8.6% CAGR) to benchmark investments and identify expansion opportunities within the British preclinical research sector.
    • Competitive Landscape Intelligence : Understand the UK CRO ecosystem, key service providers, and competitive positioning to make informed decisions about partnerships, acquisitions, or market entry strategies specific to the British market.
    • Regulatory & Infrastructure Insights : Gain detailed knowledge of UK regulatory frameworks, 3Rs compliance requirements, and research infrastructure advantages that influence market dynamics and operational strategies for humanized model providers.
    • End-User Demand Analysis : Identify specific demand drivers from UK pharmaceutical companies, biotech firms, and academic institutions to tailor product offerings, pricing strategies, and service portfolios for maximum market penetration.
    • Strategic Planning & Forecasting : Leverage UK-specific market projections through 2030 to develop long-term business strategies, resource allocation plans, and investment decisions with confidence in localized market trends and growth trajectories.

    Frequently asked questions

    What is the current size of the UK humanized mouse and rat model market?

    The UK humanized mouse and rat model market was valued at $18.1 million in 2025 and is expected to grow to $27.3 million by 2030.

    What is the projected growth rate for the UK market through 2030?

    The UK market is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.

    Which therapeutic areas are driving demand in the UK market?

    Oncology, immunology, and infectious disease research are the primary therapeutic areas driving demand for humanized models in the UK.

    Why is the UK a key market for humanized mouse and rat models?

    The UK benefits from advanced pharmaceutical and biotechnology research infrastructure, strong regulatory support, world-class research institutions, and a skilled workforce in genetic engineering.

    How has Brexit affected the UK humanized model market?

    Post-Brexit, the UK has aligned with international regulatory standards, which continues to support innovation and commercialization of humanized models while maintaining competitive advantage in European research.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status